Johnson & Johnson Ireland

Milestones as listed on jnj.com, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.

Leadership as listed on jnj.com, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.

Products and services as listed on jnj.com, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.

Sites as listed on jnj.com, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.

What public registers list for Johnson & Johnson (incl. Janssen) (group figures): clinical trials it sponsors, FDA device clearances, Irish licences, recent approvals and supply shortages. Rebuilt daily, last on 3 Oct 2026.

Clinical trials 197 in our ClinicalTrials.gov registers · 6 in the EU register

Showing 10 of 197, trials with Irish sites first. The full lists are on the sponsor pages below.

All trials by sponsor name 5 registry names

Drugs in these trials 118 compounds

EU trials register (CTIS) 6 authorised or ongoing

• A Phase 2 Study Evaluating the Safety and Efficacy of Neoadjuvant Amivantamab in Combination with Lazertinib or Chemotherapy in Resectable EGFR-Mutated Non-Small Cell Lung Cancer2025-524816-13-00 · Phase II · Ongoing
• A research trial in healthy participants to learn how a new formulation of JNJ‑77730614 is absorbed and processed by the body, and how well both the new formulation and the buccal delivery system (cup) are tolerated2026-526295-22-00 · Phase I · Authorised
• A Double-blind, Randomized, Psychoactive Placebo-controlled Study to Evaluate the Efficacy and Safety of Intranasal Esketamine 84 mg in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder in Adolescent Participants with Acute Suicidal Ideation or Behavior2024-518615-19-00 · Phase III · Ongoing
• A Phase 3 Randomized Study Comparing Ramantamig Plus Daratumumab Versus Investigator’s Choice of Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy.2026-526654-14-01 · Phase III · Authorised
• Efficacy and Safety of Nipocalimab vs Efgartigimod for Patients with Generalized Myasthenia Gravis in a Randomized, Open-label, Phase 3b, Interventional Trial Including Within Class Switching From Efgartigimod to Nipocalimab2025-521130-28-00 · Phase III · Ongoing
• A Phase 3 Randomized, Double-blind, and Active-controlled, Multicenter Study to Evaluate the Efficacy and Safety of JNJ-78934804 in Participants with Moderately to Severely Active Ulcerative Colitis2026-525923-26-00 · Phase III · Ongoing

Recent approvals

• IcotydeEMA · icotrokinra hydrochloride · 18 Sep 2026
• ImaavyEMA · nipocalimab · 28 Nov 2025

Medicine shortages 4 in the FDA list · 1 German notices

• Methylphenidate Hydrochloride Tablet, Extended ReleaseUS (FDA) · in shortage · updated 1 Oct 2026
• Rivaroxaban For SuspensionUS (FDA) · resolved · updated 18 Sep 2026
• Etravirine TabletUS (FDA) · resolved · updated 28 Apr 2026
• Itraconazole CapsuleUS (FDA) · resolved · updated 27 Feb 2026
• INVEGA 9 mg Retardtabletten - OP28(Blister)Germany (BfArM) · 3 Nov 2026 to 7 Aug 2027

A company is listed here when it is named on the shortage record; a shortage can have several manufacturers. See the US and German shortage trackers.

NICE technology appraisals 95 of its medicines · 81 current

• Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitableNICE TA1170 · Optimised · 24 Jun 2026
• Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancerNICE TA1158 · Recommended (Cancer Drugs Fund) · 28 May 2026
• Oxybutynin hydrochloride for managing neurogenic detrusor overactivity in people 6 years and over with spinal cord injury or spina bifida (terminated appraisal)NICE TA1154 · Terminated (no company submission) · 7 May 2026
• Canagliflozin for treating type 2 diabetes in people 10 to 17 years (terminated appraisal)NICE TA1137 · Terminated (no company submission) · 25 Feb 2026
• Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancerNICE TA1122 · Recommended · 21 Jan 2026
• Talquetamab for treating relapsed and refractory multiple myeloma after 3 or more treatmentsNICE TA1114 · Recommended · 3 Dec 2025
• Abiraterone (originator and generics) for treating newly diagnosed high-risk hormone‑sensitive metastatic prostate cancerNICE TA1110 · Recommended · 19 Nov 2025
• Guselkumab for treating moderately to severely active ulcerative colitisNICE TA1094 · Optimised · 28 Aug 2025

Appraisals of medicines whose first EU or US authorisation was held by this company, from our NICE appraisals register. NICE decisions apply to the NHS in England. © NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.

Group (Johnson & Johnson (incl. Janssen)): founded 1886, headquarters New Brunswick, website jnj.com. Wikidata Q333718 · Wikipedia. From Wikidata (CC0), matched by the group's SEC filer number.

How this is matched: register records are linked to this page by the organisation name they carry, here Janssen-Cilag Ltd.; Janssen Research & Development, LLC; Janssen Pharmaceutica N.V., Belgium; Janssen-Cilag International NV; Johnson & Johnson Enterprise Innovation Inc.; Janssen Scientific Affairs, LLC and 22 more. Spot a wrong match? Tell us.

Group figures for Johnson & Johnson, the parent company. From the annual reports Johnson & Johnson files with the US Securities and Exchange Commission (10-K, US GAAP), in USD as reported. Latest financial year: to Dec 2025.

R&D is shown as tagged in the filing, which for this company can exclude acquired in-process R&D. Each year is taken from the most recent annual report that includes it, so earlier years reflect any later restatement. Source: SEC EDGAR (XBRL financial data). Compare companies on the pharma company financials register.

Companies registered in Ireland 20 active in the CRO register

From the Companies Registration Office (CRO Open Data, CC BY 4.0). A company is listed when GLEIF's legal entity register links it to Johnson & Johnson as its ultimate parent, or when we checked its name and registered address by hand. Branches of foreign companies appear as "External company". Spot a missing or wrong entry? Tell us.